How Should a Clinic Plan an FHIR R5 Pilot for Care Coordination in 2026?

The direct answer

A clinic planning an FHIR R5 pilot should treat R5 as a controlled interoperability program, not as a software upgrade with a fixed start date. The immediate goal is to test a small number of care-coordination workflows—such as closed-loop referrals, discharge follow-up, medication reconciliation, or patient-reported pulse collection—using real data, documented patient consent, and measurable safety outcomes. A sensible first pilot involves 1 clinic, 2 to 4 workflow scenarios, approximately 5 to 15 participating staff members, and 90 to 180 days of observation. The team should preserve support for FHIR R4 where existing partners and operational systems still depend on it rather than assuming that an R5 label produces universal compatibility.

Also worth reading: How Can Patient Pulse Consent Workflows Streamline Clinic Coordination? · What Makes Care Coordination RPM Software Essential for Clinics? · How Can SDOH Care Coordination Platforms Turn Social Risk Into Actionable Care Plans?

FHIR R5 is the fifth major version of HL7's FHIR standard. It was published in 2023 and adds resources, profiles, terminology improvements, and a more modular definition of the base specification. Those additions are useful, but implementation quality depends more on profiles, terminology servers, authorization rules, data quality, and interface behavior than on the version number alone. A successful pilot therefore has a clinical purpose, a defined patient or partner cohort, acceptance thresholds, incident handling, and an exit decision. It should answer whether exchanging data improves work and safety, not merely whether an integration can send a valid JSON or XML message.

What is different in FHIR R5?

FHIR R5 reorganizes parts of FHIR and expands the resources available for clinical and administrative exchange. It provides improved support for areas such as evidence generation, diagnostic reports, medication knowledge, clinical reasoning artifacts, and administrative workflows, while changing or retiring some elements from earlier releases. Because the specification is modular, implementers can work with individual parts that apply to their use case instead of implementing the entire specification. That modularity can make a pilot cleaner, but it also means teams must explicitly select the conformance resources, profiles, extensions, value sets, and implementation guides needed for their workflow.

For care-coordination SaaS, the relevant questions are narrower than the full scope of FHIR. A patient-pulse platform may need Patient, Observation, Questionnaire, QuestionnaireResponse, CarePlan, Task, ServiceRequest, and communication or referral resources, depending on the service. If a clinic only collects weekly symptom scores and routes elevated results to a care team, it may not need to exchange every resource supported by R5. A smaller, semantically accurate exchange is usually safer than a broad integration that sends incomplete or poorly mapped clinical records.

Compatibility also requires care. R5 is backward-compatible in many areas through carefully selected mechanisms, but that does not mean every R4 server will accept every R5 payload without adaptation. XML and JSON remain available, although JSON adoption is common in modern APIs. A vendor should test its exact package, profiles, and message types against the systems in the pilot. Claims that a product is “FHIR R5” should be converted into concrete questions: which resources and profiles are supported, against which published Implementation Guide or version, with which mandatory elements, and what validation results are available?

Choosing a clinically useful pilot

Start with a workflow where delayed or missing information creates measurable patient risk or staff effort. Closed-loop referral management is a strong candidate because the team can measure receipt, acceptance, rejection reasons, time to first review, completion, and communication with the receiving service. Discharge follow-up is another candidate when the organization can connect hospital discharge information to outreach, patient-reported symptoms, and documented escalation. A patient-pulse workflow works when responses include usable thresholds, an owner, a response-time expectation, and a way to distinguish urgent from routine results.

Avoid choosing a pilot merely because the vendor offers many endpoints. Define the sending organization, receiving organization, patient population, data categories, clinical owner, technical owner, and start and stop conditions before interface development begins. A baseline period of 30 to 60 days can establish current referral completion, callback time, duplicate data entry, and escalation performance. If those baseline figures are unreliable, improvement cannot be calculated credibly. For a small clinic, 100 to 300 real transactions may be enough to expose structural problems, but the sample should reflect the highest-risk situations and must not be restricted to unusually easy cases.

A useful pilot statement is: “For eligible adult cardiology patients receiving a new referral, can conformant exchange reduce unprocessed referrals from 20% to below 10% within 120 days while keeping critical demographic and clinical mismatches below 1%?” The numbers should be adjusted to local conditions, but the structure matters. A target without denominator, time frame, cohort, and measurement method is not operational. The clinical team should also set a stop rule—for example, pausing the pilot if critical patient identity errors, unauthorized disclosures, or urgent results without an acknowledged owner exceed an agreed level.

How to structure the implementation

The first 2 to 4 weeks should establish governance, workflow mapping, and conformance scope. Name an executive sponsor, a clinical safety lead, a product owner, an integration engineer, a privacy or security reviewer, and representatives from participating clinics. Document the current process from referral creation through completion, including phone calls, faxes, portals, spreadsheets, and manual chart entry. Map every data element to a FHIR resource, field, code system, value set, and source of truth. Where the source is uncertain, resolve that uncertainty before launch rather than allowing two systems to disagree silently.

Weeks 3 through 6 are usually appropriate for build and vendor validation using synthetic or de-identified test data unless local rules expressly allow a controlled test environment to contain real patient data. Validate structure, terminology, business rules, and behavior rather than checking only whether a request returns HTTP 200. Test missing mandatory fields, invalid codes, duplicate submissions, changed patient identifiers, unavailable terminology services, delayed responses, retries, and unauthorized access. Acceptance testing should include scenarios such as a referral arriving without contact details, an urgent result sent when the destination is unavailable, and a patient response that crosses a threshold after office hours.

A 90-day production pilot can then run in phases: 5 to 10 users or one care team, followed by one partner and a larger cohort if safety measures hold. A 180-day period is preferable when the workflow includes monthly outcomes or enough volume is needed to estimate rare failure modes. The team should hold weekly operational reviews for the first month and at least monthly thereafter. Record every rejected message, manual override, safety event, and work-around. At the end, compare pilot results with the baseline, estimate annual operating effort, and decide whether to expand, revise, or stop.

Comparison of implementation approaches

There is no single universally correct FHIR R5 approach. The appropriate option depends on interoperability requirements, internal technical capacity, partner readiness, and whether the organization needs advanced clinical semantics or only reliable transfer of a limited dataset.

A third practical option is to use a certified integration platform, interface engine, or FHIR server that handles validation, terminology, subscriptions, and version negotiation. This can reduce custom engineering, but it does not remove the need to choose profiles and manage clinical workflows. Managed services often cost more in platform fees and configuration than a narrowly built interface, yet may be economical when several clinics share the implementation. The correct comparison is total cost over at least 3 years, including licenses, interface work, terminology access, hosting, support, validation, security review, and staff time for manual exceptions.

Cost, staffing, and procurement

FHIR itself is an open standard, so there is no required license fee for using its specifications. Implementation is not free. A narrowly scoped internal pilot may require roughly 2 to 4 person-months across product, integration, clinical, security, and testing work, although a complex cross-organization program can require 6 to 12 full-time-equivalent staff for 6 to 12 months. A small vendor engagement might be priced in the low five figures, while a broader platform implementation can move into six figures; these are planning ranges, not official FHIR prices.

Ongoing costs may include a FHIR server or interface engine, hosting, observability, terminology subscription or hosting, identity management, consent controls, support, conformance testing, and clinical training. Clinics should separate one-time integration expense from annual operating cost and per-transaction charges. Contracts should define who pays for new profiles, partner onboarding, major FHIR upgrades, custom mappings, and urgent support. Ask whether R5 capabilities are included in the current subscription or require an edition, usage tier, professional-services package, or approved implementation guide.

Procurement language should be specific. Instead of requiring “FHIR R5 compliance,” request a resource-and-profile matrix, version of each implementation guide, list of supported interactions, terminology dependencies, test results, known limitations, and upgrade policy. Confirm whether “R5” means the full release, a selected R5 content module, or only R5 versions of APIs that originated in R4. Also evaluate data residency, breach notification, audit logs, access controls, business associate arrangements, disaster recovery objectives, and export rights. Price should be considered after technical and clinical fit, not as the first filter.

Common mistakes and avoidable failure modes

One common mistake is treating the release number as a proxy for usefulness. An interface can pass basic validation while sending a clinically meaningless observation, wrong units, or an answer that no one is accountable to review. Another error is implementing resources before defining the workflow. This produces an attractive API demonstration but leaves fax calls, duplicate entry, unanswered tasks, and escalation gaps untouched. A pilot should include the human operating model, not just the endpoint list.

Teams also underestimate terminology and identity problems. A score of 8 may be valid numerically but useless without a code, unit, scale, time period, provenance, and interpretation. Patient matching can be worse than schema validation: two records may be technically valid yet refer to different people. Use verified identifiers, explicit matching rules, reconciliation procedures, and protected handling of mismatches. The design should preserve the source identifier and provenance so an operator can investigate discrepancies.

Avoid parallel “shadow” systems that quietly disagree, indefinite pilot extensions without new evidence, and success metrics based only on message volume. Set a decision date, define the minimum safe volume, and pre-agree on what counts as failure. Expansion should be paused when a critical error harms a patient, data is disclosed improperly, urgent results lack an owner, or corrective work exceeds the planned capacity. FHIR reduces syntactic friction; it does not remove clinical responsibility.

When to act, expand, or stop

A clinic should act now if it has a defined interoperability problem, a willing clinical partner, and an accountable owner. There is no universal requirement to be on the final FHIR release before exchanging a limited, well-tested dataset. Waiting can itself be costly when staff continue manual work, but rushing into R5 can create compatibility and safety risk. The practical decision is based on partner demand, available conformance packages, internal capacity, and expected patient benefit.

Expansion should occur only after at least one production cycle has been observed, not merely after a successful demonstration. By day 90, a pilot might target 95% or higher successful processing for eligible records, 99% or higher identity agreement for matched participants, and 100% documented ownership of urgent items. Those are example thresholds and must be adapted to the risk of the workflow. Also require no unresolved high-severity safety or privacy defect, acceptable staff effort, and partner willingness to continue.

Stop or redesign when success depends on undocumented manual intervention, when required terminology cannot be maintained, or when partners cannot reliably exchange the minimum dataset. A failed pilot can still produce value by identifying whether the selected profile, vendor, partner, or workflow is wrong. Document the failure with dates, denominators, incident counts, root causes, and remediation owners. For FHIR R5 planning in 2026, the best decision is usually a bounded R5-capable pilot with R4 compatibility where needed, clear safety thresholds, and expansion tied to evidence from real care coordination rather than vendor terminology.